Lower drug dose shows promise for safer transplants
NCT ID NCT07319000
Summary
This study tested whether using a lower dose of the drug cyclophosphamide after stem cell transplants could effectively prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial involved 35 adults with blood cancers who received stem cell transplants from related donors. Researchers wanted to see if this lower-dose approach could reduce side effects while still protecting patients from GVHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Universitario de Monterrey
Monterrey, 64460, Mexico
Conditions
Explore the condition pages connected to this study.